Zobrazeno 1 - 4
of 4
pro vyhledávání: '"K. V. Gorelov"'
Autor:
A. R. Titova, N. V. Kosyakina, T. S. Polikarpova, Yu. S. Skorodumova, V. A. Polivanov, K. V. Gorelov
Publikováno v:
Безопасность и риск фармакотерапии, Vol 11, Iss 1, Pp 46-51 (2023)
A periodic benefit–risk evaluation report (PBRER) is a retrospective evaluation document enabling marketing authorisation holders to present the results of a critical analysis of the benefit–risk ratio of a medicinal product. PBRER submission and
Externí odkaz:
https://doaj.org/article/a05cd00c0c6540c6a68c6cc1f18366a7
Autor:
N. Yu. Velts, E. O. Zhuravleva, G. V. Kutekhova, N. V. Tereshkina, A. O. Lovkova, K. V. Gorelov, V. A. Polivanov, S. M. Gyulakhmedova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 3, Pp 259-268 (2022)
Adverse drug reactions (ADRs) are recorded throughout the lifecycle of a medicinal product. In the post-marketing period, new ADRs are primarily identified via drug safety signals. In order to assess a signal and establish causality between an advers
Externí odkaz:
https://doaj.org/article/d800373c951347cfb8c2c216c68f7e36
Publikováno v:
Patient-Oriented Medicine and Pharmacy. 1:41-48
The results and the degree of safety of hypoglycaemic drugs are presented. The current work analyses the safety of the use of sulfonylurea derivatives, biguanides, thiazolidinediones, meglitinides and α-glucosidase inhibitors according to clinical s
Publikováno v:
Journal of Volgograd State Medical University. 18:169-176
Good pharmacovigilance practices have been introduced for continuous and updated exchange of information on drug safety. The pharmacovigilance system provides continuous monitoring of medicines, which can reduce morbidity, mortality and costs to heal